Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study

lovo‐cel (bb1111; LentiGlobin for sickle cell disease [SCD]) gene therapy (GT) comprises autologous transplantation of hematopoietic stem and progenitor cells transduced with the BB305 lentiviral vector encoding a modified β‐globin gene (β(A‐T87Q)) to produce anti‐sickling hemoglobin (HbA(T87Q)). Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanter, Julie, Thompson, Alexis A., Pierciey, Francis J., Hsieh, Matthew, Uchida, Naoya, Leboulch, Philippe, Schmidt, Manfred, Bonner, Melissa, Guo, Ruiting, Miller, Alex, Ribeil, Jean‐Antoine, Davidson, David, Asmal, Mohammed, Walters, Mark C., Tisdale, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092845/
https://www.ncbi.nlm.nih.gov/pubmed/36161320
http://dx.doi.org/10.1002/ajh.26741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092845/
https://www.ncbi.nlm.nih.gov/pubmed/36161320
http://dx.doi.org/10.1002/ajh.26741

Ejemplares similares